#Opinión | ➡️ ¿De qué sirve un avance científico si no llega al #paciente?
Paloma Anguita, Head of Medical Affairs Spain de #AstellasPharma, reflexiona en su columna👇
https://www.consalud.es/opinion/cuando-la-investigacion-transforma-vidas-paciente-ciencia-y-acceso-como-prioridades-en-salud.html
Paloma Anguita, Head of Medical Affairs Spain de #AstellasPharma, reflexiona en su columna👇
https://www.consalud.es/opinion/cuando-la-investigacion-transforma-vidas-paciente-ciencia-y-acceso-como-prioridades-en-salud.html
June 29, 2026 at 12:39 PM
#Opinión | ➡️ ¿De qué sirve un avance científico si no llega al #paciente?
Paloma Anguita, Head of Medical Affairs Spain de #AstellasPharma, reflexiona en su columna👇
https://www.consalud.es/opinion/cuando-la-investigacion-transforma-vidas-paciente-ciencia-y-acceso-como-prioridades-en-salud.html
Paloma Anguita, Head of Medical Affairs Spain de #AstellasPharma, reflexiona en su columna👇
https://www.consalud.es/opinion/cuando-la-investigacion-transforma-vidas-paciente-ciencia-y-acceso-como-prioridades-en-salud.html
#SMC #AstellasPharma #Astellas #metastaticbladdercancer #bladdercancer #Enfortumabvedotin #pembrolizumab #NHSScotland #Scottishmedicinesconsortium #unresectableurothelialcancer #metastaticurothelialcancer #SMCrecommendation #EV302phase3clinicaltrial #advancedbladdercancer
zurl.co/2s8ch
zurl.co/2s8ch
SMC backs first-line metastatic bladder cancer combination after trial results - PharmaTimes
Enfortumab vedotin and pembrolizumab recommended for NHS Scotland
pharmatimes.com
May 12, 2026 at 11:29 AM
#SMC #precisiononcology #precisonmedicine #gastriccancer #zolbetuximab #NHSScotland #AstellasPharma #advancedgastriccancer #gastrooesophagealjunctioncancer #adenocarcinomatumours #biomarkers #cancerbiology #phase3clinicaltrials #SPOTLIGHT #GLOW
zurl.co/7GCPi
zurl.co/7GCPi
Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment - PharmaTimes
Decision introduces zolbetuximab for eligible patients in NHS Scotland
pharmatimes.com
January 20, 2026 at 12:04 PM
#womenshealth #Fezolinetant #menopausesymptoms #phase4data #AstellasPharma #Astellas #OPTIONVMSobservationalstudy #vasomotorsymptoms #VMS #menopause #menopausalVMS #Hotflashes #nightsweats #TheMenopauseSociety #sleepoutcomes #PROMISSDSF8b #actigraphyendpoints
pharmatimes.com/news/fezolin...
pharmatimes.com/news/fezolin...
Fezolinetant shows real-world promise for menopause symptoms - PharmaTimes
Preliminary phase 4 data highlights improvements in sleep, work productivity and quality of life
pharmatimes.com
October 29, 2025 at 10:43 AM
Thank you to our amazing sponsors for powering #KISymposium2025! Sanofi, AstellasPharma, @milliporesigma.bsky.social, Pfizer, CanCollaborate, Qiagen, Window Therapeutics, @mofollp.bsky.social, @novartis.bsky.social
June 27, 2025 at 4:31 PM
Thank you to our amazing sponsors for powering #KISymposium2025! Sanofi, AstellasPharma, @milliporesigma.bsky.social, Pfizer, CanCollaborate, Qiagen, Window Therapeutics, @mofollp.bsky.social, @novartis.bsky.social
A letter from #AstellasPharma has warned that serious liver injury has been observed with #fezolinetant (#Veoza), a non-hormonal alternative to #HRT
HRT alternative could cause serious liver injury, manufacturer warns
Serious liver injury has been observed with fezolinetant (Veoza; Astellas Pharma), a non-hormonal alternative to hormone replacement therapy (HRT), its manufacturer has warned. In a letter sent to…
pharmaceutical-journal.com
March 4, 2025 at 3:54 PM
A letter from #AstellasPharma has warned that serious liver injury has been observed with #fezolinetant (#Veoza), a non-hormonal alternative to #HRT